JPMorgan initiated coverage of Upstream Bio (UPB) with an Overweight rating and $38 price target Upsteam’s lead asset is verekitug, a recombinant human IgG1 monoclonal antibody that binds the thymic ...

JPMorgan downgraded Bluebird Bio (BLUE) to Underweight from Neutral without a price target post the Q3 report. Bluebird missed on sales and notably reduced its cash runway to into Q1 of 2025 from in ...

bluebird bio (NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations ...

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (UPB) (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...